Autologous pancreatic islet transplantation in human bone marrow

Research output: Contribution to journalArticle

Abstract

The liver is the current site of choice for pancreatic islet transplantation, even though it is far from being ideal. We recently have shown in mice that the bone marrow (BM) may be a valid alternative to the liver, and here we report a pilot study to test feasibility and safety of BM as a site for islet transplantation in humans. Four patients who developed diabetes after total pancreatectomy were candidates for the autologous transplantation of pancreatic islet. Because the patients had contraindications for intraportal infusion, islets were infused in the BM. In all recipients, islets engrafted successfully as shown by measurable posttransplantation C-peptide levels and histopathological evidence of insulin-producing cells or molecular markers of endocrine tissue in BM biopsy samples analyzed during follow-up. Thus far, we have recorded no adverse events related to the infusion procedure or the presence of islets in the BM. Islet function was sustained for the maximum follow-up of 944 days. The encouraging results of this pilot study provide new perspectives in identifying alternative sites for islet infusion in patients with type 1 diabetes. Moreover, this is the first unequivocal example of successful engraftment of endocrine tissue in the BM in humans.

Original languageEnglish
Pages (from-to)3523-3531
Number of pages9
JournalDiabetes
Volume62
Issue number10
DOIs
Publication statusPublished - Oct 2013

Fingerprint

Islets of Langerhans Transplantation
Bone Marrow
Pancreatectomy
Autologous Transplantation
C-Peptide
Liver
Type 1 Diabetes Mellitus
Islets of Langerhans
Insulin
Biopsy
Safety

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Medicine(all)

Cite this

Autologous pancreatic islet transplantation in human bone marrow. / Maffi, Paola; Balzano, Gianpaolo; Ponzoni, Maurilio; Nano, Rita; Sordi, Valeria; Melzi, Raffaella; Mercalli, Alessia; Scavini, Marina; Esposito, Antonio; Peccatori, Jacopo; Cantarelli, Elisa; Messina, Carlo; Bernardi, Massimo; Del Maschio, Alessandro; Staudacher, Carlo; Doglioni, Claudio; Ciceri, Fabio; Secchi, Antonio; Piemonti, Lorenzo.

In: Diabetes, Vol. 62, No. 10, 10.2013, p. 3523-3531.

Research output: Contribution to journalArticle

@article{f9735ab424ad476483a066606d3466a6,
title = "Autologous pancreatic islet transplantation in human bone marrow",
abstract = "The liver is the current site of choice for pancreatic islet transplantation, even though it is far from being ideal. We recently have shown in mice that the bone marrow (BM) may be a valid alternative to the liver, and here we report a pilot study to test feasibility and safety of BM as a site for islet transplantation in humans. Four patients who developed diabetes after total pancreatectomy were candidates for the autologous transplantation of pancreatic islet. Because the patients had contraindications for intraportal infusion, islets were infused in the BM. In all recipients, islets engrafted successfully as shown by measurable posttransplantation C-peptide levels and histopathological evidence of insulin-producing cells or molecular markers of endocrine tissue in BM biopsy samples analyzed during follow-up. Thus far, we have recorded no adverse events related to the infusion procedure or the presence of islets in the BM. Islet function was sustained for the maximum follow-up of 944 days. The encouraging results of this pilot study provide new perspectives in identifying alternative sites for islet infusion in patients with type 1 diabetes. Moreover, this is the first unequivocal example of successful engraftment of endocrine tissue in the BM in humans.",
author = "Paola Maffi and Gianpaolo Balzano and Maurilio Ponzoni and Rita Nano and Valeria Sordi and Raffaella Melzi and Alessia Mercalli and Marina Scavini and Antonio Esposito and Jacopo Peccatori and Elisa Cantarelli and Carlo Messina and Massimo Bernardi and {Del Maschio}, Alessandro and Carlo Staudacher and Claudio Doglioni and Fabio Ciceri and Antonio Secchi and Lorenzo Piemonti",
year = "2013",
month = "10",
doi = "10.2337/db13-0465",
language = "English",
volume = "62",
pages = "3523--3531",
journal = "Diabetes",
issn = "0012-1797",
publisher = "American Diabetes Association Inc.",
number = "10",

}

TY - JOUR

T1 - Autologous pancreatic islet transplantation in human bone marrow

AU - Maffi, Paola

AU - Balzano, Gianpaolo

AU - Ponzoni, Maurilio

AU - Nano, Rita

AU - Sordi, Valeria

AU - Melzi, Raffaella

AU - Mercalli, Alessia

AU - Scavini, Marina

AU - Esposito, Antonio

AU - Peccatori, Jacopo

AU - Cantarelli, Elisa

AU - Messina, Carlo

AU - Bernardi, Massimo

AU - Del Maschio, Alessandro

AU - Staudacher, Carlo

AU - Doglioni, Claudio

AU - Ciceri, Fabio

AU - Secchi, Antonio

AU - Piemonti, Lorenzo

PY - 2013/10

Y1 - 2013/10

N2 - The liver is the current site of choice for pancreatic islet transplantation, even though it is far from being ideal. We recently have shown in mice that the bone marrow (BM) may be a valid alternative to the liver, and here we report a pilot study to test feasibility and safety of BM as a site for islet transplantation in humans. Four patients who developed diabetes after total pancreatectomy were candidates for the autologous transplantation of pancreatic islet. Because the patients had contraindications for intraportal infusion, islets were infused in the BM. In all recipients, islets engrafted successfully as shown by measurable posttransplantation C-peptide levels and histopathological evidence of insulin-producing cells or molecular markers of endocrine tissue in BM biopsy samples analyzed during follow-up. Thus far, we have recorded no adverse events related to the infusion procedure or the presence of islets in the BM. Islet function was sustained for the maximum follow-up of 944 days. The encouraging results of this pilot study provide new perspectives in identifying alternative sites for islet infusion in patients with type 1 diabetes. Moreover, this is the first unequivocal example of successful engraftment of endocrine tissue in the BM in humans.

AB - The liver is the current site of choice for pancreatic islet transplantation, even though it is far from being ideal. We recently have shown in mice that the bone marrow (BM) may be a valid alternative to the liver, and here we report a pilot study to test feasibility and safety of BM as a site for islet transplantation in humans. Four patients who developed diabetes after total pancreatectomy were candidates for the autologous transplantation of pancreatic islet. Because the patients had contraindications for intraportal infusion, islets were infused in the BM. In all recipients, islets engrafted successfully as shown by measurable posttransplantation C-peptide levels and histopathological evidence of insulin-producing cells or molecular markers of endocrine tissue in BM biopsy samples analyzed during follow-up. Thus far, we have recorded no adverse events related to the infusion procedure or the presence of islets in the BM. Islet function was sustained for the maximum follow-up of 944 days. The encouraging results of this pilot study provide new perspectives in identifying alternative sites for islet infusion in patients with type 1 diabetes. Moreover, this is the first unequivocal example of successful engraftment of endocrine tissue in the BM in humans.

UR - http://www.scopus.com/inward/record.url?scp=84891494667&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84891494667&partnerID=8YFLogxK

U2 - 10.2337/db13-0465

DO - 10.2337/db13-0465

M3 - Article

C2 - 23733196

AN - SCOPUS:84891494667

VL - 62

SP - 3523

EP - 3531

JO - Diabetes

JF - Diabetes

SN - 0012-1797

IS - 10

ER -